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Abstract Peroxisome proliferator-activated receptor (PPAR)Q
transcription factor has been implicated in anti-inflammatory
response. Of the compounds tested, apigenin, chrysin, and
kaempferol significantly stimulated PPARQ transcriptional
activity in a transient reporter assay. In addition, these three
flavonoids strongly enhanced the inhibition of inducible cyclooxy-
genase and inducible nitric oxide synthase promoter activities in
lipopolysaccharide-activated macrophages which contain the
PPARQ expression plasmids. However, these three flavonoids
exhibited weak PPARQ agonist activities in an in vitro
competitive binding assay. Limited protease digestion of PPARQ
suggested these three flavonoids produced a conformational
change in PPARQ and the conformation differs in the receptor
bound to BRL49653 versus these three flavonoids. These results
suggested that these three flavonoids might act as allosteric
effectors and were able to bind to PPARQ and activate it, but its
binding site might be different from the natural ligand
BRL49653. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are
transcription factors belonging to the nuclear receptor gene
family [1]. PPARs bind to speci¢c response elements as het-
erodimers with the retinoid X receptor and activate transcrip-
tion in response to a variety of endogenous and exogenous
ligands, including certain polyunsaturated fatty acids, arachi-
donic acid metabolites [2], and some anti-diabetic drugs [3]
and non-steroidal anti-in£ammatory drugs (NSAIDs) [4].
Currently, PPARs subfamily has been de¢ned as PPARK,
PPARL (also called PPARN and NUC1) and PPARQ. Three
PPAR isoforms di¡er in their tissue distribution and ligand
speci¢city [5]. PPARK is predominantly expressed in tissues
exhibiting high catabolic rate of fatty acids (heart, liver, and
kidney), whereas PPARN expression is ubiquitous, and its
physiological role is unclear. PPARQ is expressed predomi-
nantly in adipose tissue, the adrenal gland, spleen, large colon
and the immune system [6^9]. Several lines of evidence indi-
cated that PPARQ plays an important role in regulating adi-
pocyte di¡erentiation and glucose homeostasis [10]. Both
PPARK and PPARQ have been shown that also have anti-
in£ammatory actions through activating by arachidonic acid
metabolites. PPARK bind and be activated by leukotriene B4
[11], and the levels are induced at the transcriptional level by
anti-in£ammatory glucocorticoids [12]. PPARQ are activated
by the prostaglandin D2 metabolite 15-deoxy-v12;14 prosta-
glandin J2 (15d-PGJ2) and synthetic anti-diabetic thiazolidine-
dione drugs (e.g. BRL49653 and ciglitizone) and resulted in
negatively regulating the expression of pro-in£ammatory
genes, and suppressing tumor cell growth [13^16]. Further-
more, both PPARK and PPARQ are activated by a number
of NSAIDs, such as indomethacin [4]. Recently, the PPARQ
agonists have been considered to inhibit production of mono-
cyte in£ammatory cytokines and the expression of inducible
nitric oxide synthase (iNOS) [17,18].
The £avonoids are a diverse family of chemicals commonly
found in fruits and vegetables. Flavonoids are plant polyphe-
nolic compounds, which comprise several classes including
£avonols, £avanones, £avanols and £avans. Epidemiological
studies have shown that the consumption of vegetable, fruits
and tea is associated with a decreased risk of cancer and
cardio-vascular diseases, and £avonoids are believed to play
an important role in preventing these diseases [19]. Numerous
numbers of this family have anti-carcinogenic [20], anti-in-
£ammatory [21], cytostatic [22], apoptotic [18], anti-oxidant
[23], anti-angiogenic [24] and estrogenic [25] activities. Several
reports have also shown that £avonoids are potent modula-
tors of both the expression, and activities of speci¢c cyto-
chrome P450 genes/proteins [26]. These data indicate that cer-
tain £avonoids have attracted attention as possible
chemoprotective or chemotherapeutic agents.
NSAIDs such as aspirin, sodium salicylate, and indometha-
cin exert their anti-in£ammatory e¡ects in part by inhibition
of inhibitor UB (IUB) kinase-L (IKK-L), thereby preventing
activation by nuclear factor-UB (NF-UB) of genes involved
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Table 1
Chemical structures of the various £avonoids tested for the induction of PPARQ activity in RAW246.7 cells
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in the in£ammatory response [27]. However, indomethacin
and several other NSAIDs (fenoprofen, ibuprofen, and £ufe-
namic acid) are also PPARQ ligands and block production of
in£ammatory cytokines in human monocytes [17]. In addition,
Ricote et al. [13] also demonstrated that treatment of perito-
neal macrophages with 15d-PGJ2 or several synthetic PPARQ
ligands reduce the expression of iNOS by interferon-Q (IFN-Q)
and inhibited induction of gelatinase B and scavenger receptor
A gene transcription in response to phorbol ester stimulation.
Recently, we reported that apigenin and related £avonoids
could suppress the transcriptional activity of cyclooxygenase
(COX)-2 and iNOS in part through inhibition of IKK activity
[28]. The current study was designed to determine whether the
anti-in£ammatory e¡ects of £avonoids were correlative with
their activation of PPARQ.
2. Materials and methods
2.1. Chemicals
Lipopolysaccharide (LPS) (Escherichia coli 0127:B8), £avone,
5-methoxy£avone, 7,8-dihydroxy£avone, apigenin, 3-hydroxy£avone,
kaempferol, morin, quercetin, myricetin, rutin, genistein, indometha-
cin were purchased from Sigma Chemical Co. (St Louis, MO, USA).
Chrysin, luteolin, tangeretin, galangin, ¢setin, pinocembrin, naringe-
nin, isosakuranetin, eriodictyol, hesperetin, naringin, and biochanin A
were purchased from Extrasynthese Inc. (Genay, France). Mouse
IFN-Q was purchased from RpD systems Inc. (Minneapolis, MN,
USA). Two kinds of tea polyphenols, (3)-epigallocatechin-3-gallate
and thea£avin-3,3P-digallate were puri¢ed as previously described [29].
2.2. Cell culture
The mouse macrophage cell lines RAW264.7 (ATCC, T1B71) were
cultured as previously described [28]. Thioglycollate-elicited peritoneal
macrophages were obtained from speci¢c pathogen-free female Balb/c
mice as previously described [30]. For all assays except the luciferase
assay, cells were plated in 60 mm dishes at 5U106 cells/dish and
allowed to grow for 18^24 h. Treatment with vehicle (0.1% DMSO),
test compounds and/or LPS or IFN-Q were carried out under serum-
free conditions.
2.3. Determination of prostaglandin E2 (PGE2) and nitrite
The cultured medium of control and treated cells were collected,
centrifuged, and stored at 370‡C, until tested. The level of PGE2
released into culture media was quanti¢ed using a speci¢c enzyme
immunoassay according to the manufacturer’s instructions (Amer-
sham). The nitrite concentration in the cultured medium was mea-
sured as an indicator of NO production according to the Griess re-
action [28].
2.4. Plasmids
The PPARQ expression plasmid and AOx-TK reporter plasmid were
generously provided by Professor Christopher K. Glass (California
University) [13].
The mouse iNOS promoter plasmid was generously provided by
Professor Charles J. Lowenstein (Johns Hopkins University) [31].
The mouse COX-2 promoter plasmid containing a 1035 bp fragment,
3966 to +70 relative to the transcription start, and constructed as
previously described [28]. To generate the pGEX-2T-PPARQ LBD
chimeric receptor expression plasmid, cDNA encoding the ligand
binding domains (LBD) of the mouse PPARQ1(amino acids 174^
475) were ampli¢ed by polymerase chain reaction and subcloned
into the pGEX-2T expression plasmid. Transient cotransfection and
luciferase activity assay using these plasmids were performed as de-
scribed previously [28].
2.5. Ligand binding assay
The glutathione S-transferase (Gst)^PPARQ LBD was expressed in
JM109 E. coli [32] and the fusion proteins were bound to the gluta-
thione Sepharose-4B beads according to the manufacturer’s instruc-
tions (Pharmacia Biotech). For competition binding assay, 10 Wl of
glutathione Sepharose-4B beads containing 0.1 Wg of Gst^PPARQ
LBD chimeric protein were incubated with or without unlabeled £a-
vonoids at 4‡C for 12 h in bu¡er containing 10 mM Tris (pH 7.4), 50
mM KCl, 10 mM dithiothreitol and proteinase inhibitors, then added
[3H]BRL49653 (speci¢c activity, 60 Ci/mmol) for additional 8 h.
Bound [3H]BRL49653 was precipitated from free radioactivity by
centrifugation, and washed three times with PBS. The beads contain-
ing [3H]BRL49653 were collected and quantitated by liquid scintilla-
tion counting.
2.6. Limited protease digestion assay
The protease digestion assays were performed by the method of
Allen et al. [33], with some modi¢cation. The PPARQ expression plas-
mid [13] was used to synthesize 35S-radiolabeled PPARQ in a coupled
transcription/translation system according to the protocol of the man-
ufacturer (Promega). Approximately 5 Wl of the transcription/trans-
lation reactions was preincubated with 1 Wl of tested compounds for
20 min at 25‡C. Trypsin was added and allowed to proceed for 10 min
at 25‡C, then terminated by the addition of SDS sample loading bu¡-
er and boiling for 8 min. The products of the digestion were separated
by electrophoresis through a 12% SDS^polyacrylamide gel. Labeled
PPARQ was visualized by autoradiography.
3. Results
3.1. Apigenin, chrysin, and kaempferol activated PPARQ in
macrophages
A series of £avonoids including £avone, 5-methoxy£avone,
7,8-dihydroxy£avone, apigenin, 3-hydroxy£avone, kaempfer-
ol, morin, quercetin, myricetin, rutin, genistein, chrysin, luteo-
lin, tangeretin, galangin, ¢setin, pinocembrin, naringenin, iso-
sakuranetin, eriodictyol, hesperetin, naringin, and biochanin
A, tea polyphenols (Table 1), and indomethacin were ¢rst
tested with regard to their activation e¡ects on PPARQ in
RAW264.7 cells. As RAW264.7 cells express very low levels
of PPARQ [13] and required transfection of a PPARQ expres-
sion plasmid. The cells therefore allowed a direct assessment
of the role of PPARQ in mediating the e¡ects of these £avo-
noids on macrophage gene expression. The PPARQ expression
plasmid was cotransfected into RAW264.7 cells with a report-
er construct containing three copies of the acyl CoA oxidase
PPAR responsive element upstream of the thymidine kinase
(TK) promoter driving luciferase gene expression. In the ab-
sence of a cotransfected PPARQ expression plasmid, treatment
of RAW264.7 macrophages with the tested £avonoids at 10
WM had little e¡ect on activation of PPARQ. However, when a
PPARQ expression plasmid was cotransfected into the cells,
apigenin, chrysin, and kaempferol signi¢cantly induced the
PPARQ 8.13-, 5.60- and 7.66-fold, respectively (P6 0.05)
(Fig. 1A). The positive control of indomethacin (100 WM)
strongly induced the PPARQ activity 13.34-fold which was
compared with the mock experiment. Apigenin, chrysin, and
kaempferol increased the PPARQ activity in a dose-dependent
manner, with the EC50 of approximately 5 WM, 10 WM, and
10 WM, respectively (Fig. 1B). However, there was a cytotoxic
e¡ect in RAW264.7 cells with 20 WM of apigenin and a de-
crease in the activation of PPARQ. Flavone, 7,8-dihydroxy£a-
vone, 3-hydroxy£avone, luteolin, galangin, genistein, biocha-
nin A also increased the PPARQ activities when RAW264.7
cells were transfected with the expression plasmid of PPARQ.
However, the induction folds of these £avonoids showed no
signi¢cant di¡erence in activation of PPARQ compared with
control RAW264.7 cells that were transfected with PPARQ
expression plasmid (Figs. 1A and 2, 2.74-fold). The other
tested £avonoids were unable to activate the PPARQ, and
the data were not shown in Fig. 1A.
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3.2. Apigenin, chrysin and kaempferol enhanced the inhibition
of COX-2 and iNOS promoters’ activities in a
PPARQ-dependent manner
RAW264.7 cells was transiently transfected with the report-
er plasmids of COX-2 or iNOS and both promoters’ activities
were markedly increased when RAW264.7 cells were treated
with LPS (Fig. 2). Both promoters’ activities were inhibited by
concurrent treatment of the cells with apigenin, chrysin and
kaempferol. Moreover, transfection of PPARQ expression
plasmid enhanced the inhibitory e¡ects of these three £avo-
noids (Fig. 2A,B). The results suggested that apigenin, chrysin
and kaempferol inhibited the promoters’ activities of COX-2
and iNOS genes partially through PPARQ pathways.
3.3. Apigenin, chrysin, and kaempferol bound with PPARQ and
induced conformational change in PPARQ
We next sought to determine whether these three £avonoids
activated PPARQ through direct interaction with the PPARQ
receptor. The abilities of these £avonoids to bind to PPARQ
were assessed in a competition binding assay using
[3H]BRL49653 and the glutathione Sepharose beads contain-
ing Gst^PPARQ LBD fusion protein. As shown in Fig. 3,
[3H]BRL49653 bound speci¢cally and saturably to Gst^PPARQ
LBD beads with a Kd of 8 nM (Fig. 3A,B). No binding was
detected in control Gst^PPARQ LBD beads (data not shown).
Apigenin, chrysin, and kaempferol competed with
[3H]BRL49653 for binding to the PPARQ LBD in a dose-de-
pendent manner, with an IC50 of approximately 50 WM. Pro-
Fig. 1. E¡ects of apigenin, chrysin, and kaempferol on the activa-
tion of PPARQ in cells. RAW264.7 cells were cotransfected with the
AOx-TK reporter plasmid and PPARQ expression plasmid (open
squares) or PPARQ mock plasmid (closed squares) and L-galactosi-
dase expression vector (pcDNA lacZ) as internal control. A: Trans-
fected cells were treated with 10 WM of £avonoids, or 100 WM of in-
domethacin for 18 h, and cell extracts subsequently assayed for
luciferase and L-galactosidase activities as described in Section 2.
The values were represented as means þ S.E.M. of triplicate tests.
The numbers were obtained from ratios of the induction fold of
transfected PPARQ expression to mock expression and indicated
in the ¢gure. *P6 0.05 (Student’s t-test) versus control (2.74).
B: Transfected cells were treated with various concentrations of api-
genin (closed circles), chrysin (open circles), and kaempferol (closed
triangles) for 18 h, and cells extracts assayed for luciferase and L-
galactosidase activities as described above. Con., control; Indo, in-
domethacin; Api, apigenin; Chr, chrysin; DHF, 7,8-dihydroxy£a-
vone; Fla, £avone; HFl, 3-hydroxy£avone; Lut, luteolin; Gal, gal-
angin; Kae, kaempferol; Bio, biochanin A; Gen, genistein.
Fig. 2. Apigenin, chrysin and kaempferol enhanced the inhibition of
the promoter activities of COX-2 and iNOS in a PPARQ-dependent
manner. RAW264.7 cells were cotransfected with a COX-2 (A) or
iNOS (B) promoter-luciferase reporter plasmid, pcDNA lacZ inter-
nal control vector, and either a PPARQ expression plasmid or mock
plasmid as indicated. Cells were treated with LPS (50 ng/ml) and
BRL49653 (20 WM), or various £avonoids (10 WM) for 18 h, and
extracts subsequently assayed for luciferase and L-galactosidase ac-
tivities as described in Section 2. The values were represented as
means þ S.E.M. of triplicate tests. *P6 0.05, compared with the in-
dividual test of mock expression (Student’s t-test).
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teolytic analysis have been used for several experiments to
demonstrate that ligands of nuclear receptor can, upon bind-
ing, speci¢cally alter the conformation of the receptor [33,34].
This conformational change was re£ected by the increased
resistance of the receptor to partial digestion by proteases.
To determine if there were conformational di¡erences in
PPARQ bound to these three £avonoids, a limited trypsin
digestion on a [35S]methionine-labeled PPARQ was performed.
As shown in Fig. 4, incubation of PPARQ with increasing
concentrations of trypsin in the absence of ligand led to the
complete digestion of PPARQ. In contrast, BRL49653 induced
a stronger protection of the 22, 29 and 30 kDa fragments.
These three £avonoids binding yielded 29 and 30 kDa pro-
tected fragments, especially a 30 kDa band. These results in-
dicated that these three £avonoids were able to bind to PPARQ
and £avonoid-bound PPARQ had a distinct trypsin digestion
pattern compared to the BRL49653-bound receptor.
4. Discussion
Flavonoids are naturally occurring plant polyphenols found
in abundance in the diets rich in fruit, vegetables and plant-
derived beverages such as tea. The PPARQ ligands share cer-
tain structural characteristics including a lipophilic backbone
and an acid moiety, usually a carboxylate. Although £avo-
noids only have a similar lipophilic backbone, several £avo-
noids also bind to PPARQ in vitro (Fig. 4). Several reports
have shown that treatment of various ¢broblast and mesen-
chymal stem cell lines with PPARQ ligands, including 15d-
PGJ2, the anti-diabetic drugs, and several NSAIDs, promotes
their e⁄cient conversion to adipocytes [3,4,35^37]. However,
treatment of C3H10T1/2 stem cells with 10 WM of apigenin,
chrysin, and kaempferol failed to promote adipocytes di¡er-
entiation as indicated by Oil Red O staining (data not shown).
Northern blot analysis indicated that PPARQ expression levels
were not induced in response to treatment with these three
£avonoids in ¢broblast cells (data not shown). As we know,
adipocyte di¡erentiation required forced expression of PPARQ
and was signi¢cantly enhanced in the presence of PPARQ
activators [38]. For example, treatment of C3H10T1/2 cells
with BRL49653 increased PPARQ expression levels approxi-
mately three-fold, and resulted in e⁄cient adipocyte di¡eren-
tiation [3]. In addition, while £avonoids were potent inhibitors
of several kinases involved in signal transduction, mainly pro-
tein kinase C [39] and tyrosine kinase [40,41]. However, adi-
pocyte di¡erentiation is characterized by a coordinate increase
in adipocyte-speci¢c gene expression through activating of
gene transcription. Therefore, they were insu⁄cient to initiate
the adipogenic signaling cascade in a mesenchymal stem cell
line. Devchand et al. [11] proposed that leukotriene B4, an
agonist of the related receptor PPARK, has anti-in£ammatory
activity. The £avonoids might also activate the PPARK and
have anti-in£ammatory e¡ects, but PPARK is not expressed in
activated macrophages.
Of the tested £avonoids (Table 1), the groups of £avanones
and £avan-3-ol were ine⁄cient on activation of PPARQ. This
result suggested that the C2^C3 double bond of C ring was
essential for their activation of PPARQ. Some £avonoids of
£avones, £avonols and iso£avones groups were able to acti-
vate PPARQ. The activation of PPARQ seems to be dependent
on the number and the position of hydroxyl residues. The
hydroxyl residues of the 5 and 7 positions of the A ring and
4P position of the B ring were important factors for activation
of PPARQ, such as in apigenin, chrysin and kaempferol. How-
ever, the additional hydroxyl residue of the 3P position of the
B ring resulted in a decrease of the activation of PPARQ, such
as in luteolin and quercetin.
Fig. 3. The binding capacity of apigenin, chrysin, and kaempferol
to PPARQ in vitro. A: Glutathione Sepharose beads containing the
Gst^PPARQ LBD fusion protein were incubated with increasing
concentrations of [3H]BRL49653. Non-speci¢c binding was deter-
mined using 500-fold excess of unlabeled BRL49653. Closed trian-
gles, total binding; closed circles, non-speci¢c binding; open circles,
speci¢c binding. B: Scatchard analysis of speci¢c binding data from
A. Linear regression yielded a Kd of 8 nM. Similar results were ob-
tained in three independent experiments performed in duplicate.
C: Competition binding analysis was performed with Sepharose^
GST^PPARQ LBD beads and 5 nM [3H]BRL49653 in the presence
of various concentrations of apigenin (closed circles), chrysin (open
triangles), or kaempferol (closed squares) as unlabeled competitors.
Similar results were obtained in two independent experiments per-
formed in duplicate.
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These three £avonoids were able to activate PPARQ in a
transient reporter assay, with an EC50 of approximately 5^10
WM. However, they needed a higher concentration to bind to
Gst^PPARQ in an in vitro competitive binding assay (Fig. 3).
The high concentration of IC50 (50 WM) suggested that these
three £avonoids might not directly bind to PPARQ or bind to
PPARQ in the other sites. A limited protease digestion assay
(Fig. 4) indicated that PPARQ has a conformational di¡erence
in the receptor bound to the three £avonoids versus natural
ligand BRL49653. These results suggested that these three
£avonoids might act as allosteric e¡ectors, and were able to
bind to PPARQ and activate it, but its binding site might be
di¡erent from the natural ligand BRL49653. Based on the
di¡erent binding kinetics, it may interpret the fact that these
three £avonoids did not promote di¡erentiation of C3H10T1/
2 stem cells to adipocyte. Our previous studies have shown
that apigenin was able to inhibit IKK activity and prevent the
activation of NF-UB, and then suppress the promoter activ-
ities of COX-2 and iNOS [28]. Therefore, apigenin was a more
stronger inhibitor of COX-2 and iNOS promoters activities
than BRL49653 in the absence and presence of transfected
PPARQ expression plasmid (Fig. 2). However apigenin was
more e¡ective in the presence of PPARQ than absence of
PPARQ in inhibition of COX-2 and iNOS promoters. These
results indicated that these three £avonoids inhibited the ex-
pression of COX-2 and iNOS partially through activating
PPARQ. In RAW264.7 cells, the base level of PPARQ protein
was very low, so BRL49653 could not activate it to suppress
the activities of COX-2 and iNOS promoters in the absence of
transfected PPARQ expression plasmid.
Our results suggested that certain £avonoids could activate
PPARQ to inhibit the protein expression of COX-2. Indome-
thacin was able to inhibit COX activity without a¡ecting the
protein levels of PPARs at lower concentration [42]. At a
higher concentration, we thought that anti-in£ammatory ac-
tivity of indomethacin might be also mediated through acti-
vation of PPARQ followed by inhibition of COX expression,
since indomethacin also acts as a PPARQ agonist, promoting
adipocyte di¡erentiation.
Our previous studies demonstrated that the anti-in£amma-
tory properties of apigenin might be mediated through inhi-
bition of IKK activity. In this study, we showed that apigenin
was also an e⁄cacious activator of PPARQ which regulated
in£ammatory responses. These results suggested that apigenin,
chrysin, and kaempferol were possible activators of PPARQ,
and might have therapeutic applications in in£ammatory dis-
eases, such as atherosclerosis and rheumatoid arthritis. These
¢ndings also provide a signi¢cant molecular basis for explain-
ing how dietary £avonoids are active in preventing cancer and
in£ammation.
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